About the program

Owing to sustained efforts over recent years the landscape of Alzheimer’s disease research has, and continues to evolve from the molecular to the human level.

This undoubtedly benefits the ongoing development of new therapeutic targets and biomarkers, but this can create a challenge for you, the treating clinician.

So how can you be informed about current breakthroughs and change, understand the rationale behind novel therapies, and implement this knowledge into your practice?

Here we break down the current understanding of Alzheimer’s disease with a model of pathology that you can refer to and explore at any time. These complex mechanisms are broken down into manageable, interlinked steps, and complemented with expert commentary and supplementary articles.

Revise and reinforce your learning with a downloadable illustrative diagram of the model.

Meet our expert

M Heneka

Prof Dr med Michael Heneka
Director, Luxembourg Centre For Systems Biomedicine, University of Luxembourg, Luxembourg

Michael Heneka is a board-certified neurologist and clinician-scientist with over 25 years of experience in studying neurodegenerative diseases at experimental, preclinical and clinical levels. He has a long-standing interest in immunology and neuroscience. While the main focus of his work is related to dementia and Alzheimer’s disease, he has also been working on Amyotrophic Lateral Sclerosis and Parkinson’s disease. At the clinical level, he had established a neurodegenerative outpatient unit at both the University of Münster and the University of Bonn in Germany.

From 2016 to 2021, Prof Heneka led the department of Neurodegenerative Disease and Geriatric Psychiatry in Bonn. In January 2022, he was appointed the Director of the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg and Principal Investigator in the Neuroinflammation group (Heneka Lab).


Michael Heneka has NO financial disclosures to declare.


: Amyloid beta
AD: Alzheimer’s disease
APOE: Apolipoprotein E
APP: Amyloid precursor protein
ASC: Apoptosis-associated speck-like protein
BBB: blood–brain barrier
BIN: Bridging integrator
C3, C1q: Complement proteins
CLU: Clusterin
CNS: Central nervous system
GLP-1(RA): Glucagon-like peptide 1 (receptor agonists)
IL: Interleukin
LPS: Lipopolysaccharide
NAFLD: Non-alcoholic fatty liver disease
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells
NLRP3: NLR family pyrin domain containing 3
NO: Nitric oxide
PLCG: Phospholipase C gamma
PSEN: Presenilin
ROS: Reactive oxygen species
T2D: Type 2 diabetes
TNF: Tumor necrosis factor
TREM: Triggering receptor expressed on myeloid cells